Who pays the best (and worst) in biopharma? A look at typical employee salaries

Recent data shows that full-time life sciences employees’ average salaries rose by about 9% from 2023 to 2024, with U.S. pharmaceutical sciences professionals now earning an average base salary of about $191,800 in 2025 (Pharma Diversity Job Board, 2025).

Job posting datasets show that directors and associate directors in pharma and biotech are the best‑paid tier, with mean maximum listed salaries around $230,000 (Drug Discovery Trends, 2024).

Median salary for Medical Science Liaison (MSL) roles in biopharma is about $186,000, with individual‑contributor MSLs at top companies like Genentech, Gilead, AstraZeneca, Vertex, and GSK grouping around $210,000–$224,000 (MSL Mastery, 2025).

Across 175+ biotech and pharma companies, median employee compensation ranges from roughly $12,400 at the low end to over $670,000 at the high end, with a typical mid‑range around $200,000 (Bench International, 2023).

Life‑sciences salary reports indicate that senior‑level R&D, regulatory, and commercial roles (e.g., VPs, CMOs, CSOs, market‑access leaders) often exceed $200,000 and can reach $350,000–$500,000 in total compensation in top markets such as Switzerland and Denmark (Panda, 2026).

Lower‑end roles (e.g., some manufacturing, lab, or support positions) can still fall into the $40,000–$70,000 range, highlighting a wide internal pay gap within the sector (Drug Discovery Trends, 2024).